<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Org Med Chem Lett</journal-id><journal-id journal-id-type="iso-abbrev">Org Med Chem Lett</journal-id><journal-title-group><journal-title>Organic and Medicinal Chemistry Letters</journal-title></journal-title-group><issn pub-type="epub">2191-2858</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26548988</article-id><article-id pub-id-type="pmc">4970432</article-id><article-id pub-id-type="publisher-id">10</article-id><article-id pub-id-type="doi">10.1186/s13588-014-0010-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Synthesis and antileishmanial evaluation of some 2,3-disubstituted-4(3<italic>H</italic>)-quinazolinone derivatives</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" deceased="no" equal-contrib="no"><name><surname>Birhan</surname><given-names>Yihenew Simegniew</given-names></name><address><email>yihenews@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" deceased="no" equal-contrib="no"><name><surname>Bekhit</surname><given-names>Adnan Ahmed</given-names></name><address><email>adnbekhit@yahoo.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" deceased="no" equal-contrib="no"><name><surname>Hymete</surname><given-names>Ariaya</given-names></name><address><email>hymete@yahoo.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label>Department of Chemistry, Natural and Computational Science College, Debre Markos University, Debre Markos, Ethiopia </aff><aff id="Aff2"><label>2</label>Department of Pharmaceutical Chemistry, Alexandria University, Alexandria, 21215 Egypt </aff><aff id="Aff3"><label>3</label>Department of Pharmaceutical Chemistry and Pharmacognosy, School of Pharmacy, Addis Ababa University, Addis Ababa, Ethiopia </aff></contrib-group><pub-date pub-type="epub"><day>17</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>17</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>4</volume><elocation-id>10</elocation-id><history><date date-type="received"><day>25</day><month>5</month><year>2014</year></date><date date-type="accepted"><day>3</day><month>9</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; Birhan et al.; licensee Springer. 2014</copyright-statement><license license-type="open-access"><license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Leishmaniasis is a neglected tropical parasitic diseases affecting millions of people around the globe. Quinazolines are a group of compounds with diverse pharmacological activities. Owing to their promising antileishmanial activities, some 3-aryl-2-(substitutedstyryl)-4(3<italic>H</italic>)-quinazolinones were synthesized in good yields (65.2% to 86.4%).</p></sec><sec><title>Results</title><p>The target compounds were synthesized by using cyclization, condensation, and hydrolysis reactions. The structures of the synthesized compounds were determined using elemental microanalysis, infrared (IR), and proton nuclear magnetic resonance (<sup>1</sup>H NMR). The <italic>in vitro</italic> antileishmanial activities of the synthesized compounds were evaluated using <italic>Leishmania donovani</italic> strain. All the synthesized compounds displayed appreciable antileishmanial activities (IC<sub>50</sub> values, 0.0128 to 3.1085 &#x003bc;g/ml) as compared to the standard drug miltefosine (IC<sub>50</sub> = 3.1911 &#x003bc;g/ml). (<italic>E</italic>)-2-(4-chlorostyryl)-3-<italic>p</italic>-tolyl-4(3<italic>H</italic>)-quinazolinone (<bold>7</bold>) is the compound with the most promising antileishmanial activities (IC<sub>50</sub> = 0.0128 &#x003bc;g/ml) which is approximately 4 and 250 times more active than the standard drugs amphotericin B deoxycholate (IC<sub>50</sub> = 0.0460 &#x003bc;g/ml) and miltefosine (IC<sub>50</sub> = 3.1911 &#x003bc;g/ml), respectively.</p></sec><sec><title>Conclusions</title><p>The results obtained from this investigation indicate that the synthesized and biologically evaluated quinazoline compounds showed promising antileishmanial activities and are good scaffolds for the synthesis of different antileishmanial agents.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s13588-014-0010-1) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Quinazolinones</kwd><kwd>Leishmania</kwd><kwd>Antileishmanial activities</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Leishmanisis is a neglected tropical disease resulting from infection of macrophages by obligate intracellular parasites of the genus <italic>Leishmania</italic>[<xref ref-type="bibr" rid="CR1">1</xref>]-[<xref ref-type="bibr" rid="CR3">3</xref>]. It is a public health problem in at least 88 countries with an estimated 350 million people at risk. The estimated global prevalence of all forms of the disease is 12 million. Every year, 1.5 to 2 million new cases and 70,000 deaths occur due to cutaneous leishmaniasis (CL). In addition, 500,000 new cases and 59,000 deaths from visceral leishmaniasis (VL) occur annually [<xref ref-type="bibr" rid="CR4">4</xref>]. The number of cases of leishmaniasis is increasing globally due to <italic>Leishmania</italic>/HIV co-infection [<xref ref-type="bibr" rid="CR5">5</xref>],[<xref ref-type="bibr" rid="CR6">6</xref>], international travel, and migration of immigrants and refugees from endemic regions [<xref ref-type="bibr" rid="CR7">7</xref>],[<xref ref-type="bibr" rid="CR8">8</xref>].</p><p>The prophylactic treatment of leishmaniasis mainly rely on vector and reservoir control [<xref ref-type="bibr" rid="CR9">9</xref>]-[<xref ref-type="bibr" rid="CR11">11</xref>]. Control of reservoir host and vector is difficult due to high coast, operational difficulties, and frequent relapses in the host [<xref ref-type="bibr" rid="CR12">12</xref>]. Although considerable effort has been made to produce vaccine candidates for the treatment of leishmaniasis, there is no vaccine against any form of human leishmaniasis yet [<xref ref-type="bibr" rid="CR13">13</xref>]-[<xref ref-type="bibr" rid="CR17">17</xref>].</p><p>Pentavalent antimonials (Sb<sup>V</sup>) have been used for the treatment of leishmania infections. Unfortunately, in many parts of the world, the parasite has become resistant to Sb<sup>V</sup>[<xref ref-type="bibr" rid="CR18">18</xref>]. Treatment failure to sodium stibogluconate (SSG) is observed in Eastern Sudan [<xref ref-type="bibr" rid="CR19">19</xref>] and in Tigray, Northern Ethiopia [<xref ref-type="bibr" rid="CR20">20</xref>]. Recent reports showed that pentamidine also developed resistance as well as difficulties in treating patients with <italic>Leishmania</italic>/HIV co-infection [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p>Combination chemotherapy has improved prospects for decreasing the emergence of drug resistance, increasing activity, and reducing required doses and thereby toxic side effects. In the previous study, WR 279,396 (a topical formulation containing 15% paromomycin and 0.5% gentamicin) was found to be safe and effective against CL caused by <italic>Leishmania major</italic>[<xref ref-type="bibr" rid="CR22">22</xref>]. In addition, AmBisome-paromomycin is the most cost-effective combination among miltefosine-paromomycin and AmBisome-miltefosine [<xref ref-type="bibr" rid="CR23">23</xref>]. So far, no combination chemotherapy has been used in treatment programs, except paromomycin/SSG [<xref ref-type="bibr" rid="CR24">24</xref>].</p><p>Tremendous quinazoline derivatives are synthesized in the past two decades, using different synthetic pathways [<xref ref-type="bibr" rid="CR25">25</xref>]-[<xref ref-type="bibr" rid="CR30">30</xref>], due to their diverse pharmacological activities [<xref ref-type="bibr" rid="CR31">31</xref>]-[<xref ref-type="bibr" rid="CR36">36</xref>] including antileishmanial activities [<xref ref-type="bibr" rid="CR37">37</xref>]-[<xref ref-type="bibr" rid="CR40">40</xref>]. These reports indicate that several quinazolines were synthesized and tested for their antileishmanial activities, with the aim of discovering alternative chemotherapeutic agents for the development of new antileishmanials. Promising antileishmanial activities were observed in some 4-aminoquinazoline [<xref ref-type="bibr" rid="CR37">37</xref>], indolo[2,1-<italic>b</italic>]quinazoline-6,12-dione [<xref ref-type="bibr" rid="CR38">38</xref>], and 2,3-disubstituted-4(3<italic>H</italic>)-quinazolinone derivatives [<xref ref-type="bibr" rid="CR39">39</xref>],[<xref ref-type="bibr" rid="CR40">40</xref>]. As part of the efforts to discover less toxic and more effective drug analogues for the treatment of leishmaniasis, we synthesized some 2,3-disubstituted-4(3<italic>H</italic>)-quinazolinones and tested their <italic>in vitro</italic> antileishmanial activities.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Chemicals and reagents</title><p>Anthranilic acid, acetic anhydride, aniline, <italic>p</italic>-toluidine, <italic>o</italic>-toluidine, acetone, dimethylsulfoxide, anhydrous zinc chloride, <italic>p</italic>-chlorobenzaldehyde, <italic>p</italic>-nitrobenzaldehyde, <italic>p</italic>-hydroxybenzaldehyde, chloroform, absolute ethanol, resazurin sodium salt, anhydrous petroleum ether, distilled water, iodine, HCl, and KOH were used in the study.</p></sec><sec id="Sec4"><title>Instruments and apparatuses</title><p>Melting points were determined in open capillaries using electro-thermal 9100 melting point apparatus and were uncorrected. Infrared (IR) spectra in nujol were recorded with the SHIMADZU 8400SP FT-IR spectrophotometer (Shimadzu Corporation, Nakagyo-ku, Kyoto, Japan), and proton nuclear magnetic resonance (<sup>1</sup>H NMR) spectral data were performed on Bruker Avance DMX400 FT-NMR spectrometer (Bruker, Billerica, MA, USA) using tetramethyl silane (TMS) as internal standard. Silica gel TLC plates of 0.25-mm thickness were used in the study.</p></sec><sec id="Sec5"><title>Experimental animals and strains</title><p>Swiss albino male mice of weight 20 to 32 g and age 6 to 8 weeks (for acute toxicity test) were obtained from Biomedical Laboratory, Department of Biology, Faculty of Science, AAU. <italic>Leishmania donovani</italic> isolate used in this study was obtained from Leishmania Diagnosis and Research Laboratory (LDRL) culture bank, School of Medicine, AAU.</p></sec><sec id="Sec6"><title>Culture medium and conditions</title><p>RPMI-1640, 10% heat-inactivated fetal calf serum (HIFCS), 1% penicillin-streptomycin, and 1% <sc>l</sc>-glutamine were supplied to make a complete culture medium. The <italic>L. donovani</italic> isolate was grown first on Novy-MacNeal-Nicolle (NNN) medium and then in tissue culture flasks containing RPMI-1640 medium supplemented with 10% HIFCS and 1% 100 IU penicillin/ml-100 &#x003bc;g/ml streptomycin solution at 22&#x000b0;C for promastigotes.</p></sec><sec id="Sec7"><title>Reference drugs</title><p>Miltefosine/hexadecylphosphocholine (AG Scientific, San Diego, CA, USA) and amphotericin B deoxyhcholate (Fungizone&#x000ae;, ER Squibb, Middlesex, UK) were employed as reference drugs in the <italic>in vitro</italic> antileishmanial activity testing of the synthesized compounds.</p></sec><sec id="Sec8"><title>Preparation of stock and working solutions</title><p>Stock solutions of 10 mg/ml of the synthesized compounds were prepared by dissolving each compound in DMSO. Stock solutions were diluted using complete RPMI to obtain aliquots of 10 &#x003bc;g/ml. Then, threefold serial dilution with complete RPMI gave the final six working concentrations (10, 3.33, 1.11, 0.37, 0.12, and 0.04 &#x003bc;g/ml) of each of the synthesized compounds. Amphotericin B deoxycholate and miltefosine, which were used as a positive control for comparison of the antileishmanial activities of the test compounds, were also made in threefold serial dilutions. All the prepared drugs were stored at &#x02212;20&#x000b0;C and retrieved only during use [<xref ref-type="bibr" rid="CR41">41</xref>].</p></sec><sec id="Sec9"><title>In vitro antileishmanial activity</title><p>In a 96-well microtiter plate, 100 &#x003bc;l of each of the seven threefold serial dilutions of synthesized compounds were added in triplicate wells. Then, 100 &#x003bc;l of suspension of parasites (3.0 &#x000d7; 10<sup>6</sup> promastigotes/ml of <italic>L. donovani</italic>) was added in duplicate. Some of the wells contained only the parasites which served as a positive control. The media and DMSO alone acted as a negative control. The contents of the plates were then maintained in humidified atmosphere at 22&#x000b0;C under 5% CO<sub>2</sub>.</p><p>After 68 h of incubation, 10 &#x003bc;l of fluorochrome resazurin solution (12.5 mg dissolved in 100 ml of distilled water) was added into each well. The fluorescence intensity was measured after a total incubation period of 72 h using Victor3 Multilabel Counter (PerkinElmer, Waltham, MA, USA), at an excitation wavelength of 530 nm and emission wavelength of 590 nm [<xref ref-type="bibr" rid="CR42">42</xref>]. The IC<sub>50</sub> values were evaluated from sigmoidal dose-response curves using GraphPad Prism 5.0 software (GraphPad Software, Inc., San Diego, CA, USA).</p></sec><sec id="Sec10"><title>In vivo acute toxicity test</title><p>The oral acute toxicity of compound <bold>7</bold> that exhibited promising antileishmanial activity was investigated using male Swiss albino mice (approximately 20 g each) following reported methods [<xref ref-type="bibr" rid="CR43">43</xref>]. The experimental animals were divided into six groups (containing six mice per group) and fasted overnight. Groups <bold>1-5</bold> received compound <bold>7</bold> suspended in a vehicle containing 1% gum acacia, in doses of 10, 50, 100, 200, and 300 mg/kg, respectively. The sixth group received vehicle containing 1% gum acacia (served as a control group) at a maximum dose of 1 ml/100 g of body weight by oral route. The mice were observed closely for 24 h with special attention to the first 4 h. Acute toxicity signs were checked in the test mice.</p></sec><sec id="Sec11"><title>Statistical analysis</title><p>The IC<sub>50</sub> values for <italic>in vitro</italic> promastigotes assay of synthesized compounds were evaluated from sigmoidal dose-response curves using computer software GraphPad Prism 5.0.</p></sec></sec><sec id="Sec12"><title>Results and discussion</title><sec id="Sec13"><title>Chemistry of the synthesized compounds</title><p>Synthesis of the target compounds involved the formation of <bold>2-5</bold> and <bold>10</bold> as intermediates. It was accomplished using nucleophilic reaction, nucleophilic with ring opening and closing, condensation reaction, and hydrolysis reactions. The target compounds are synthesized in a good yield, which ranged from 65.2% to 86.4% (Table <xref rid="Tab1" ref-type="table">1</xref>). All the synthesized compounds were readily soluble in DMSO and chloroform except compound <bold>12</bold> which is readily soluble in acetone. Spectral data (IR and <sup>1</sup>H NMR) of the synthesized compounds were in full agreement with the proposed structures.<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Physical constants and percent yield of the synthesized compounds</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Test compound</th><th>Molecular formula</th><th>Molecular weight (g/mol)</th><th>% yield</th><th>Melting point (&#x000b0;C)</th><th><bold><italic>R</italic></bold><sub>f</sub>values [CHCl<sub>3</sub>/C<sub>6</sub>H<sub>6</sub>(9:1)]</th></tr></thead><tbody><tr><td>
<bold>6</bold>
</td><td>C<sub>22</sub>H<sub>17</sub>ClN<sub>2</sub>O</td><td>360.85</td><td>68.3</td><td>201 to 203</td><td>0.520</td></tr><tr><td>
<bold>7</bold>
</td><td>C<sub>23</sub>H<sub>19</sub>ClN<sub>2</sub>O</td><td>374.87</td><td>65.2</td><td>189 to 191</td><td>0.577</td></tr><tr><td>
<bold>8</bold>
</td><td>C<sub>23</sub>H<sub>18</sub>N<sub>3</sub>O<sub>3</sub></td><td>384.41</td><td>74.8</td><td>214 to 216</td><td>0.422</td></tr><tr><td>
<bold>9</bold>
</td><td>C<sub>23</sub>H<sub>18</sub>N<sub>3</sub>O<sub>3</sub></td><td>384.41</td><td>76.2</td><td>235 to 237</td><td>0.642</td></tr><tr><td>
<bold>11</bold>
</td><td>C<sub>26</sub>H<sub>24</sub>N<sub>2</sub>O<sub>4</sub></td><td>428.49</td><td>86.4</td><td>151 to 153</td><td>0.781</td></tr><tr><td>
<bold>12</bold>
</td><td>C<sub>22</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub></td><td>342.40</td><td>80.3</td><td>298 to 300</td><td>0.524</td></tr><tr><td>
<bold>13</bold>
</td><td>C<sub>24</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub></td><td>386.45</td><td>82.2</td><td>196 to 198</td><td>0.711</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec14"><title>Biological activity testing results</title><sec id="Sec15"><title>In vitro antileishmanial activity of the synthesized compounds</title><p>The antipromastigote activities of the synthesized compounds and the standard antileishmanial drugs (amphotericin B deoxycholate and miltefosine) were evaluated using the clinical isolate of <italic>L. donovani</italic> strain. The IC<sub>50</sub> of the synthesized and reference drugs were evaluated from fluorescence characteristic of AlamarBlue&#x000ae; (resazurin) (Trek Diagnostic Systems, Inc., Cleveland, OH, USA) which is soluble, stable in culture medium, non-toxic to cells, and does not affect the secretary abilities of cells [<xref ref-type="bibr" rid="CR44">44</xref>]. The test works as a cell viability and proliferation indicator through the conversion of resazurin to resorufin via reduction. The amount of fluorescence produced is proportional to the number of living cells [<xref ref-type="bibr" rid="CR45">45</xref>],[<xref ref-type="bibr" rid="CR46">46</xref>].</p><p>The quinazolinone derivatives synthesized were shown to have good antileishmanial activity which was in line with the previous reports [<xref ref-type="bibr" rid="CR37">37</xref>]-[<xref ref-type="bibr" rid="CR40">40</xref>]. All the tested compounds exhibited better antileishmanial activity than the standard drug miltefosine as shown in Table <xref rid="Tab2" ref-type="table">2</xref>. Among them, compound <bold>7</bold> was found to have a very promising antileishmanial activity with an IC<sub>50</sub> value of 0.0128 &#x003bc;g/ml which was 250 times superior than miltefosine (3.1911 &#x003bc;g/ml). Compounds <bold>8</bold> and <bold>11</bold> were 30 times more active than miltefosine. Compounds <bold>6</bold> and <bold>12</bold> were 10 times and twice more active than miltefosine, respectively. Compounds <bold>9</bold> and <bold>13</bold> were as active as miltefosine.<table-wrap id="Tab2"><label>Table 2</label><caption><p>
<bold>Antipromastigote activity (IC</bold>
<sub><bold>50</bold></sub>
<bold>) of the synthesized compounds</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Test compounds</th><th>IC<sub>50</sub>values (&#x003bc;g/ml)</th><th>IC<sub>50</sub>values (ng/ml)</th></tr></thead><tbody><tr><td>
<bold>6</bold>
</td><td>0.3014</td><td>301.40</td></tr><tr><td>
<bold>7</bold>
</td><td>0.0128</td><td>12.80</td></tr><tr><td>
<bold>8</bold>
</td><td>0.1085</td><td>108.50</td></tr><tr><td>
<bold>9</bold>
</td><td>2.7017</td><td>2,701.70</td></tr><tr><td>
<bold>11</bold>
</td><td>0.1086</td><td>108.60</td></tr><tr><td>
<bold>12</bold>
</td><td>1.6472</td><td>1,647.20</td></tr><tr><td>
<bold>13</bold>
</td><td>3.1085</td><td>3,108.50</td></tr><tr><td>Miltefosine</td><td>3.1911</td><td>3,191.10</td></tr><tr><td>Amphotericin B</td><td>0.0460</td><td>46.00</td></tr></tbody></table><table-wrap-foot><p>IC<sub>50</sub>: effective concentration required to achieve 50% growth inhibition (in &#x003bc;g/ml).</p></table-wrap-foot></table-wrap></p><p>All the synthesized compounds except compound <bold>7</bold> displayed weak antileishmanial activities as compared to amphotericin B deoxycholate. Better antipromastigote activity was observed for (<italic>E</italic>)-2-(4-chlorostyryl)-3-<italic>p</italic>-tolyl-4(3<italic>H</italic>)-quinazolinone (<bold>7</bold>) with an IC<sub>50</sub> value of 0.0128 &#x003bc;g/ml which is four times higher than the standard drug amphotericin B deoxycholate with an IC<sub>50</sub> value of 0.0128 &#x003bc;g/ml. (<italic>E</italic>)-2-(4-chlorostyryl)-3-<italic>p</italic>-tolyl-4(3<italic>H</italic>)-quinazolinone (<bold>7</bold>) was found to be 4 times more active than amphotericin B deoxycholate and 250 times more active than miltefosine.</p></sec><sec id="Sec16"><title>Oral acute toxicity study</title><p>Compound (<italic>E</italic>)-2-(4-chlorostyryl)-3-<italic>p</italic>-tolyl-4(<italic>3H</italic>)-quinazolinone (<bold>7</bold>) was observed to be devoid of any inherent acute toxicities at a maximum dose of 300 mg/kg.</p></sec></sec></sec><sec id="Sec17"><title>Experimental</title><sec id="Sec18"><title>Synthesis of target compounds</title><p>The synthesis of target compounds, 3-aryl-2-(substitutedstyryl)-4(3<italic>H</italic>)-quinazolinones (<bold>6-9</bold> and <bold>11-13</bold>), was achieved using cyclization, condensation, and hydrolysis reactions. It involved the synthesis of acetanthranil (2-methyl-3,1-benzoxazin-4-one (<bold>2</bold>)) and 3-aryl-2-methyl-4(3<italic>H</italic>)-quinazolinones (<bold>3-5</bold>) as intermediates (Scheme <xref rid="Sch1" ref-type="fig">1</xref>). The details of each reactions and reaction conditions, the summarized characteristic stretching and bending IR vibration frequencies, the elemental microanalysis, and the <sup>1</sup>H NMR chemical shift data for each of the synthesized target compounds are given below.<fig id="Sch1"><label>Scheme 1</label><caption><p>
<bold>Synthesis of 3-aryl-2-(substitutedstyryl)-4(3</bold>
<bold><italic>H</italic></bold>
<bold>)-quinazolinones using acetanthranil (2-methyl-3,1-benzoxazin-4-one (2)) and 3-aryl-2-methyl-4(3</bold>
<bold><italic>H</italic></bold>
<bold>)-quinazolinones (3-5) as intermediates.</bold>
</p></caption><graphic xlink:href="13588_2014_Article_10_Sch1_HTML" id="d30e1158"/></fig></p><sec id="Sec19"><title>General procedure for the synthesis of 2-methyl-3,1-benzoxazin-4-one (2)</title><p>A solution of anthranillic acid (<bold>1</bold>) (10 g, 0.073 mol) in acetic anhydride (25 ml) was heated under reflux for 1 h. The precipitate formed on cooling was filtered and the excess acetic anhydride was washed with anhydrous petroleum ether, where upon a solid mass is obtained. This solid mass (<bold>2</bold>), without purification, was used for subsequent reaction [<xref ref-type="bibr" rid="CR47">47</xref>].</p></sec><sec id="Sec20"><title>General procedure for the synthesis of 3-aryl-2-methyl-4(3H)-quinazolinones (3-5)</title><p>A mixture of 2-methyl-3,1-benzoxazin-4-one (<bold>2</bold>) (3 g, 0.017 mol) and equimolar amounts of aromatic amines (aniline, <italic>p</italic>-toluidine, and <italic>o</italic>-toluidine, respectively) was heated under reflux at 190&#x000b0;C for 5 h. The dark sticky mass formed were cooled and recrystallized from ethanol to yield compounds <bold>3-5</bold>, respectively [<xref ref-type="bibr" rid="CR48">48</xref>].</p></sec><sec id="Sec21"><title>General procedure for the synthesis of 3-aryl-2-(4-chlorostyryl)-4(3H)-quinazolinones (6 and 7)</title><p>To a solution of <bold>3</bold> or <bold>4</bold> (0.5 g each) in acetic anhydride (10 ml), an equimolar amount of <italic>p</italic>-chlorobenzaldehyde was added in the presence of 10 mg of anhydrous zinc chloride as a catalyst. The reaction mixture was heated under reflux for 8 h, cooled, and poured into ice-cooled water. The solid products formed (<bold>6</bold> or <bold>7</bold>) were filtered, dried, and recrystallized from chloroform/ethanol (2:1) [<xref ref-type="bibr" rid="CR49">49</xref>].</p></sec><sec id="Sec22"><title>E)-2-(4-chlorostyryl)-3-phenylquinazolin-4(3H)-one (6)</title><p>IR (Nujol) (cm<sup>&#x02212;1</sup>): 1,682 (C = O), 1,597 (C = N), and 1,224 (C-Cl). <sup>1</sup>H NMR (CDCl<sub>3</sub>) <italic>&#x003b4;</italic> (ppm): 6.33 (<italic>d</italic>, 1H, <italic>J</italic> = 15.49 Hz, vinyl-C<sub>2</sub> H), 7.23 (<italic>d</italic>, 2H, <italic>J</italic> = 8.53 Hz, 4-chlorophenyl C<sub>3,5</sub> H), 7.28 (<italic>d</italic>, 2H, <italic>J</italic> = 8.47 Hz, 4-chlorophenyl C<sub>2,6</sub> H), 7.34 (<italic>d</italic>, 2H, <italic>J</italic> = 6.82 Hz, phenyl C<sub>2,6</sub> H), 7.45 to 7.49 (<italic>m</italic>, 1H, quina-C<sub>6</sub> H), 7.58 to 7.63 (<italic>m</italic>, 3H, phenyl C<sub>3,4,5</sub> H), 7.75 to 7.79 (<italic>m</italic>, 2H, quina-C<sub>7,8</sub> H), 7.91 (<italic>d</italic>, 1H, <italic>J</italic> = 15.47 Hz, vinyl-C<sub>1</sub> H), 8.29 (<italic>d</italic>, 1H, <italic>J</italic> = 7.95 Hz, quina-C<sub>5</sub>). Anal. calcd. for C<sub>22</sub>H<sub>17</sub>ClN<sub>2</sub>O: C, 73.23; H, 4.75; Cl, 9.83; N, 7.76. Found: C, 73.64; H, 4.92; Cl, 10.22; N, 7.54.</p></sec><sec id="Sec23"><title>E)-2-(4-chlorostyryl)-3-p-tolylquinazolin-4(3H)-one (7)</title><p>IR (Nujol) (cm<sup>&#x02212;1</sup>): 1,682 (C = O), 1,597 (C = N), and 1,224 (C-Cl). <sup>1</sup>H NMR (CDCl<sub>3</sub>) <italic>&#x003b4;</italic> (ppm): 2.5 (<italic>s</italic>, 3H, <italic>p-</italic> tolyl CH<sub>3</sub>), 6.42 (<italic>d</italic>, 1H, <italic>J</italic> = 15.70 Hz, vinyl-C<sub>2</sub> H), 7.21 (<italic>d</italic>, 2H, 4-chlorophenyl C<sub>3,5</sub> H), 7.26 to 7.32 (<italic>m</italic>, 4H, <italic>p</italic>-tolyl C<sub>2,3,5,6</sub> H), 7.40 (<italic>d</italic>, 2H, 4-chlorophenyl C<sub>2,6</sub> H), 7.47 to 7.51 (<italic>m</italic>, 1H, quina-C<sub>6</sub> H), 7.79 to 7.83 (<italic>m</italic>, 2H, quina-C<sub>7,8</sub> H), 7.93 (<italic>d</italic>, 1H, vinyl-C<sub>1</sub> H), 8.32 (<italic>d</italic>, 1H, quina-C<sub>5</sub> H). Anal. calcd. for C<sub>23</sub>H<sub>19</sub>ClN<sub>2</sub>O: C, 73.69; H, 5.12; Cl, 9.46; N, 7.47. Found: C, 73.98; H, 5.38; Cl, 9.35; N, 7.21.</p></sec><sec id="Sec24"><title>General procedure for the synthesis of 3-aryl-2-(4-nitrostyryl)-4(3H)-quinazolinones (8 and 9)</title><p>To a solution of <bold>4</bold> or <bold>5</bold> (0.5 g each) in acetic anhydride (10 ml), an equimolar amount of <italic>p</italic>-nitrobenzaldehyde was added in the presence of 10 mg of anhydrous zinc chloride as a catalyst. The reaction mixture was heated under reflux for 8 h, cooled, and poured into ice-cooled water. The solid products formed (<bold>8</bold> or <bold>9</bold>) were filtered, dried, and recrystallized from chloroform/ethanol (2:1) [<xref ref-type="bibr" rid="CR49">49</xref>].</p></sec><sec id="Sec25"><title>E)-2-(4-nitrostyryl)-3-p-tolylquinazolin-4(3H)-one (8)</title><p>IR (Nujol) (cm<sup>&#x02212;1</sup>): 1,684 (C = O), 1,593 (C = N), 1,556 and 1,377 (NO<sub>2</sub>). <sup>1</sup>H NMR (CDCl<sub>3</sub>) <italic>&#x003b4;</italic> (ppm): 2.5 (<italic>s</italic>, 3H, <italic>p-</italic> tolyl CH<sub>3</sub>), 6.56 (<italic>d</italic>, 1H, <italic>J</italic> = 15.52 Hz, vinyl-C<sub>2</sub> H), 7.21 (<italic>d</italic>, 2H, <italic>J</italic> = 8.19 Hz, <italic>p-</italic> tolyl C<sub>3,5</sub> H), 7.41 (<italic>d</italic>, 2H, <italic>J</italic> = 7.97 Hz, <italic>p</italic>-tolyl C<sub>2,6</sub> H), 7.46 to 7.53 (<italic>m</italic>, 3H, 4-nitrophenyl C<sub>2,6</sub> and quina-C<sub>6</sub>), 7.77 to 7.81 (<italic>m</italic>, 2H, quina-C<sub>7,8</sub>), 8.00 (<italic>d</italic>, 1H, <italic>J</italic> = 15.52 Hz, vinyl-C<sub>1</sub>), 8.19 (<italic>d</italic>, 2H, <italic>J</italic> = 8.74 Hz, 4-nitrophenyl C<sub>3,5</sub>), 8.30 (<italic>d</italic>, 1H, <italic>J</italic> = 8.01 Hz, quina-C<sub>5</sub>). Anal. calcd. for C<sub>23</sub>H<sub>18</sub>N<sub>3</sub>O<sub>3</sub>: C, 71.86; H, 4.72; N, 10.93. Found: C, 72.12; H, 4.35; N, 11.10.</p></sec><sec id="Sec26"><title>E)-2-(4-nitrostyryl)-3-o-tolylquinazolin-4(3H)-one (9)</title><p>IR (Nujol) (cm<sup>&#x02212;1</sup>): 1,682 (C = O), 1,593 (C = N), 1,556 and 1,377 (NO<sub>2</sub>). <sup>1</sup>H NMR (CDCl<sub>3</sub>) <italic>&#x003b4;</italic> (ppm): 2.17 (<italic>s</italic>, 3H, <italic>o</italic>-tolyl CH<sub>3</sub>), 6.47 (<italic>d</italic>, 1H, <italic>J</italic> = 15.66 Hz, vinyl-C<sub>2</sub> H), 7.25 (<italic>d</italic>, 1H, <italic>J</italic> = 7.91 Hz, <italic>o</italic>-tolyl C<sub>3</sub> H), 7.44 to 7.46 (<italic>m</italic>, 3H, 4-nitrophenyl C<sub>2,6</sub> and <italic>o</italic>-tolyl C<sub>6</sub> H), 7.47 to 7.58 (<italic>m</italic>, 3H, <italic>o</italic>-tolyl C<sub>4,5</sub> and quina-C<sub>6</sub> H), 7.82 to 7.89 (<italic>m</italic>, 2H, quina-C<sub>7,8</sub> H), 8.05 (<italic>d</italic>, 1H, <italic>J</italic> = 15.56 Hz, vinyl-C<sub>1</sub> H), 8.19 (<italic>d</italic>, 2H, <italic>J</italic> = 8.73 Hz, 4-nitrophenyl C<sub>4,6</sub> H), 8.36 (<italic>d</italic>, 1H, <italic>J</italic> = 8.25 Hz, quina-C<sub>5</sub> H). Anal. calcd. for C<sub>23</sub>H<sub>18</sub>N<sub>3</sub>O<sub>3</sub>: C, 71.86; H, 4.72; N, 10.93. Found: C, 71.68; H, 4.93; N, 11.24.</p></sec><sec id="Sec27"><title>General procedure for the synthesis of 3-aryl-2-(4-acetylatedstyryl)-4(3H)-quinazolinones (10)</title><p>To a solution of <bold>3</bold> (0.5 g) in acetic anhydride (10 ml), an equimolar amount of <italic>p</italic>-hydroxybenzaldehyde was added. Anhydrous zinc chloride (10 mg) is added as a catalyst. The reaction mixture is heated under reflux for 8 h, cooled, and poured into ice-cooled water. The solid product formed (<bold>10</bold>) was filtered, dried, and recrystallized from ethanol [<xref ref-type="bibr" rid="CR49">49</xref>].</p></sec><sec id="Sec28"><title>General procedure for the synthesis of 3-aryl-2-(4-acetylatedstyryl)-4(3H)-quinazolinones (11)</title><p>To a solution of <bold>5</bold> (0.5 g) in acetic anhydride (10 ml), an equimolar amount of vanillin was added. Anhydrous zinc chloride (10 mg) is added as a catalyst. The reaction mixture is heated under reflux for 8 h, cooled, and poured into ice-cooled water. The solid product (<bold>11</bold>) was filtered, dried, and recrystallized from ethanol [<xref ref-type="bibr" rid="CR49">49</xref>].</p></sec><sec id="Sec29"><title>1E)-2-[-3,4-dihydro-3-(2-methylphenyl)-4-oxoquinazoline-2-yl)]vinyl}-2-methoxyphenyl acetate (11)</title><p>IR (Nujol) (cm<sup>&#x02212;1</sup>): 1,761 (C = O), 1,682 (C = O), 1,634 (C = N), 1,260 and 1,149 (C-O-C). <sup>1</sup>H NMR (CDCl<sub>3</sub>) <italic>&#x003b4;</italic> (ppm): 2.15 (<italic>s</italic>, 3H, phenylacetate CH<sub>3</sub>), 2.33 (<italic>s</italic>, 3H, <italic>o</italic>-tolyl CH<sub>3</sub>), 3.80 (<italic>s</italic>, 3H, methoxy -O-CH<sub>3</sub>), 6.27 (<italic>d</italic>, 1H, <italic>J</italic> = 15.44 Hz, vinyl-C<sub>2</sub> H), 6.88 to 6.93 (<italic>m</italic>, 2H, 2-methoxyphenyl C<sub>3,5</sub> H), 6.98 (<italic>d</italic>, 1H, <italic>J</italic> = 8.12 Hz, 2-methoxyphenyl C<sub>6</sub> H), 7.24 (<italic>d</italic>, 1H, <italic>J</italic> = 7.52 Hz, <italic>o</italic>-tolyl C<sub>3</sub> H), 7.42 to 7.53 (<italic>m</italic>, 4H, <italic>o</italic>-tolyl C<sub>4,5,6</sub> H and quina-C<sub>6</sub> H), 7.82 to 7.83 (<italic>m</italic>, 2H, quina-C<sub>7,8</sub> H), 7.96 (<italic>d</italic>, 1H, <italic>J</italic> = 15.48 Hz, vinyl-C<sub>1</sub> H), 8.34 (<italic>d</italic>, 1H, <italic>J</italic> = 7.88 Hz, quina-C<sub>5</sub> H). Anal. calcd. for C<sub>26</sub>H<sub>24</sub>N<sub>2</sub>O<sub>4</sub>: C, 72.88; H, 5.65; N, 6.54. Found: C, 73.11; H, 5.89; N, 6.42.</p></sec><sec id="Sec30"><title>General procedure for the synthesis of 3-aryl-2-(4-deacetylatedstyryl)-4(3H)-quinazolinones (12 and 13)</title><p>Subsequent treatment of <bold>10</bold> and <bold>11</bold> with 0.1 M alcoholic KOH (5 ml) in the presence of ethanol followed by 0.1 M HCl (6 ml) gave the corresponding 4-hydroxyl containing compounds <bold>12</bold> and <bold>13</bold> after recrystallization from ethanol [<xref ref-type="bibr" rid="CR49">49</xref>].</p></sec><sec id="Sec31"><title>E)-2-(4-hydroxystyryl)-3-phenylquinazolin-4(3H)-one (12)</title><p>IR (Nujol) (cm<sup>&#x02212;1</sup>): 3,290 (OH), 1,652 (C = O), and 1,604 (C = N). <sup>1</sup>H NMR (acetone-d<sub>6</sub>) <italic>&#x003b4;</italic> (ppm): 6.24 (<italic>d</italic>, 1H, <italic>J</italic> = 15.39 Hz, vinyl-C<sub>2</sub> H), 6.80 (<italic>d</italic>, 2H, <italic>J</italic> = 8.64 Hz, 4-hydroxyphenyl C<sub>3,5</sub> H), 7.24 (<italic>d</italic>, 2H, <italic>J</italic> = 8.62 Hz, 4-hydroxyphenyl C<sub>2,6</sub> H), 7.46 to 7.50 (<italic>m</italic>, 3H, phenyl C<sub>3,4,5</sub> H), 7.60 to 7.66 (<italic>m</italic>, 3H, quina-C<sub>6</sub>, phenyl C<sub>2,6</sub> H), 7.73 (<italic>d</italic>, 1H, <italic>J</italic> = 8.07 Hz, quina-C<sub>8</sub> H), 7.81 to 7.85 (<italic>m</italic>, 1H, quina-C<sub>7</sub> H), 7.92 (<italic>d</italic>, 1H, <italic>J</italic> = 15.43 Hz, vinyl-C<sub>1</sub> H), 8.02 (<italic>s</italic>, 1H, 4-hydroxyphenyl -OH), 8.17 (<italic>d</italic>, 1H, <italic>J</italic> = 9.18 Hz, quina-C<sub>5</sub> H). Anal. calcd. for C<sub>22</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub>: C, 7.17; H, 5.23; N, 8.18. Found: C, 76.86; H, 5.02; N, 8.38.</p></sec><sec id="Sec32"><title>E)-2-(4-hydroxy-3-methoxystyryl)-3-o-tolylquinazolin-4(3H)-one (13)</title><p>IR (Nujol) (cm<sup>&#x02212;1</sup>): 3,400 (OH), 1,683 (C = O), 1,634 (C = N), 1,211 and 1,148 (C-O-C). <sup>1</sup>H NMR (CDCl<sub>3</sub>) <italic>&#x003b4;</italic> (ppm): 2.15 (<italic>s</italic>, 3H, <italic>o</italic>-tolyl CH<sub>3</sub>), 3.80 (<italic>s</italic>, 3H, 4-hydroxy-2-methoxyphenyl -O-CH<sub>3</sub>), 6.10 (<italic>s</italic>, 1H, 4-hydroxy-2-methoxyphenyl -OH), 6.27 (<italic>d</italic>, 1H, <italic>J</italic> = 15.44 Hz, vinyl-C<sub>2</sub> H), 6.88 to 6.93 (<italic>m</italic>, 2H, 4-hydroxy-2-methoxyphenyl C<sub>3,5</sub> H), 6.98 (<italic>d</italic>, 1H, <italic>J</italic> = 8.12 Hz, 4-hydroxy-2-methoxyphenyl C<sub>6</sub> H), 7.24 (<italic>d</italic>, 1H, <italic>J</italic> = 7.52 Hz, <italic>o</italic>-tolyl C<sub>3</sub> H), 7.42 to 7.53 (<italic>m</italic>, 4H, <italic>o</italic>-tolyl C<sub>4,5,6</sub> H and quina-C<sub>6</sub> H), 7.82 (<italic>m</italic>, 2H, quina-C<sub>7,8</sub> H), 7.96 (<italic>d</italic>, 1H, <italic>J</italic> = 15.48 Hz, vinyl-C<sub>1</sub> H), 8.34 (<italic>d</italic>, 1H, <italic>J</italic> = 7.884 Hz, quina-C<sub>5</sub> H). Anal. calcd. for C<sub>24</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub>: C, 74.59; H, 5.74; N, 7.23. Found: C, 74.28; H, 5.96; N, 7.56.</p></sec></sec></sec><sec id="Sec33"><title>Conclusions</title><p>Some 3-aryl-2-(substitutedstyryl)-4(3<italic>H</italic>)-quinazolinone derivatives were synthesized and tested for their antileishamanial activities. Most of the synthesized compounds displayed better antileishmanial activities as compared to the standard drug miltefosine and lower antileishmanial activity as compared to amphotericin B deoxycholate except (<italic>E</italic>)-2-(4-chlorostyryl)-3-<italic>p</italic>-tolyl-4(3<italic>H</italic>)-quinazolinone (<bold>7</bold>). Compound <bold>7</bold> showed pronounced antileishmanial activities as compared to miltefosine and amphotericin B deoxycholate. Thus, 2,3-disubstituted-4(3<italic>H</italic>)-quinazolinones containing an aromatic substitution at 3-position and substituted styryl moiety at 2-position represent a promising matrix for the development of antileishmanial agents.</p></sec></body><back><app-group><app id="App1"><sec id="Sec34"><title>Authors&#x02019; original submitted files for images</title><p>Below are the links to the authors&#x02019; original submitted files for images.<media position="anchor" xlink:href="13588_2014_10_MOESM1_ESM.gif" id="MOESM1"><caption><p>Authors&#x02019; original file for figure 1</p></caption></media><media position="anchor" xlink:href="13588_2014_10_MOESM2_ESM.docx" id="MOESM2"><caption><p>Authors&#x02019; original file for figure 2</p></caption></media></p></sec></app></app-group><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors are thankful to Prof. Wondimagegn Mammo for his considerable support in running and interpreting the <sup>1</sup>H NMR data. The following were acknowledged: The Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University for performing the elemental microanalysis and providing some chemicals, Debre Markos University for granting study leave to Mr. Yihenew, and Addis Ababa University for financially supporting this research work.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renslo</surname><given-names>AR</given-names></name><name><surname>McKerrow</surname><given-names>JH</given-names></name></person-group><article-title>Drug discovery and development for neglected parasitic diseases</article-title><source>Nat Chem Biol</source><year>2006</year><volume>2</volume><fpage>701</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.1038/nchembio837</pub-id><pub-id pub-id-type="pmid">17108988</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McConville</surname><given-names>MJ</given-names></name><name><surname>Souza</surname><given-names>D</given-names></name><name><surname>Saunders</surname><given-names>E</given-names></name><name><surname>Likic</surname><given-names>VA</given-names></name><name><surname>Thomas</surname><given-names>N</given-names></name></person-group><article-title>Living in a phagolysosome; metabolism of Leishmania amastigotes</article-title><source>Trends Parasitol</source><year>2007</year><volume>23</volume><fpage>368</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1016/j.pt.2007.06.009</pub-id><pub-id pub-id-type="pmid">17606406</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>U</given-names></name><name><surname>Singh</surname><given-names>S</given-names></name></person-group><article-title>Insect vectors of Leishmania: distribution, physiology and their control</article-title><source>J Vector Borne Dis</source><year>2008</year><volume>45</volume><fpage>255</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">19248652</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manandhar</surname><given-names>KD</given-names></name><name><surname>Yadav</surname><given-names>TP</given-names></name><name><surname>Prajapati</surname><given-names>VK</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Rai</surname><given-names>M</given-names></name><name><surname>Dube</surname><given-names>A</given-names></name><name><surname>Srivastava</surname><given-names>ON</given-names></name><name><surname>Sundar</surname><given-names>S</given-names></name></person-group><article-title>Antileishmanial activity of nano-amphotericin B deoxycholate</article-title><source>J Antimicrob Chemother</source><year>2008</year><volume>62</volume><fpage>376</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1093/jac/dkn189</pub-id><pub-id pub-id-type="pmid">18453526</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nascimento</surname><given-names>ET</given-names></name><name><surname>Moura</surname><given-names>MLN</given-names></name><name><surname>Queiroz</surname><given-names>JW</given-names></name><name><surname>Barroso</surname><given-names>AW</given-names></name><name><surname>Araujo</surname><given-names>AF</given-names></name><name><surname>Rego</surname><given-names>EF</given-names></name><name><surname>Wilson</surname><given-names>ME</given-names></name><name><surname>Pearson</surname><given-names>RD</given-names></name><name><surname>Jeronimo</surname><given-names>SM</given-names></name></person-group><article-title>The emergence of concurrent HIV-1/AIDS and visceral leishmaniasis in Northeast Brazil</article-title><source>Trans R Soc Trop Med Hyg</source><year>2011</year><volume>105</volume><fpage>298</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1016/j.trstmh.2011.01.006</pub-id><pub-id pub-id-type="pmid">21474157</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cenderello</surname><given-names>G</given-names></name><name><surname>Pasa</surname><given-names>A</given-names></name><name><surname>Dusi</surname><given-names>A</given-names></name><name><surname>Dentone</surname><given-names>C</given-names></name><name><surname>Toscanini</surname><given-names>F</given-names></name><name><surname>Bobbio</surname><given-names>N</given-names></name><name><surname>Bondi</surname><given-names>E</given-names></name><name><surname>Bono</surname><given-names>VD</given-names></name><name><surname>Izzo</surname><given-names>M</given-names></name><name><surname>Riccio</surname><given-names>G</given-names></name><name><surname>Anselmo</surname><given-names>M</given-names></name><name><surname>Giacchino</surname><given-names>R</given-names></name><name><surname>Marazzi</surname><given-names>MG</given-names></name><name><surname>Pagano</surname><given-names>G</given-names></name><name><surname>Cassola</surname><given-names>G</given-names></name><name><surname>Viscoli</surname><given-names>C</given-names></name><name><surname>Ferrea</surname><given-names>G</given-names></name><name><surname>De Maria</surname><given-names>A</given-names></name></person-group><article-title>Varied spectrum of clinical presentation and mortality in a prospective registry of visceral leishmaniasis in a low endemicity area of Northern Italy</article-title><source>BMC Infect Dis</source><year>2013</year><volume>13</volume><fpage>248</fpage><pub-id pub-id-type="doi">10.1186/1471-2334-13-248</pub-id><pub-id pub-id-type="pmid">23718708</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herremans</surname><given-names>T</given-names></name><name><surname>Pinelli</surname><given-names>E</given-names></name><name><surname>Casparie</surname><given-names>M</given-names></name><name><surname>Nozari</surname><given-names>N</given-names></name><name><surname>Roelfsema</surname><given-names>J</given-names></name><name><surname>Kortbeek</surname><given-names>L</given-names></name></person-group><article-title>Increase of imported leishmaniasis in the Netherlands: a twelve-year overview (1996-2007)</article-title><source>Int Health</source><year>2010</year><volume>2</volume><fpage>42</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.inhe.2009.12.005</pub-id><pub-id pub-id-type="pmid">24037049</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ignatius</surname><given-names>R</given-names></name><name><surname>Loddenkemper</surname><given-names>C</given-names></name><name><surname>Woitzik</surname><given-names>J</given-names></name><name><surname>Schneider</surname><given-names>T</given-names></name><name><surname>Harms</surname><given-names>G</given-names></name></person-group><article-title>Localized leishmanial lymphadenopathy: an unusual manifestation of leishmaniasis in a traveler in southern Europe</article-title><source>Vector-Borne Zoonotic Dis</source><year>2011</year><volume>11</volume><issue>8</issue><fpage>1213</fpage><lpage>1215</lpage><pub-id pub-id-type="doi">10.1089/vbz.2011.0642</pub-id><pub-id pub-id-type="pmid">21612538</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>DP</given-names></name><name><surname>Hamilton</surname><given-names>JGC</given-names></name></person-group><article-title>Insecticide-impregnated netting as a potential tool for long-lasting control of the leishmaniasis vector Lutzomyia longipalpis in animal shelters</article-title><source>Parasites Vectors</source><year>2013</year><volume>6</volume><fpage>133</fpage><pub-id pub-id-type="doi">10.1186/1756-3305-6-133</pub-id><pub-id pub-id-type="pmid">23642213</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mascari</surname><given-names>TM</given-names></name><name><surname>Stout</surname><given-names>RW</given-names></name><name><surname>Foil</surname><given-names>LD</given-names></name></person-group><article-title>Laboratory evaluation of oral treatment of rodents with systemic insecticides for control of blood feeding sand flies (Diptera: Psychodidae)</article-title><source>Vector-Borne Zoonotic Dis</source><year>2012</year><volume>12</volume><issue>8</issue><fpage>699</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.1089/vbz.2011.0833</pub-id><pub-id pub-id-type="pmid">22607066</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaves</surname><given-names>LF</given-names></name><name><surname>Calzada</surname><given-names>JE</given-names></name><name><surname>Rigg</surname><given-names>C</given-names></name><name><surname>Valderrama</surname><given-names>A</given-names></name><name><surname>Gottdenker</surname><given-names>NL</given-names></name><name><surname>Salda&#x000f1;a</surname><given-names>A</given-names></name></person-group><article-title>Leishmaniasis sand fly vector density reduction is less marked in destitute housing after insecticide thermal fogging</article-title><source>Parasites Vectors</source><year>2013</year><volume>6</volume><fpage>164</fpage><pub-id pub-id-type="doi">10.1186/1756-3305-6-164</pub-id><pub-id pub-id-type="pmid">23742709</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thakur</surname><given-names>CP</given-names></name><name><surname>Kumar</surname><given-names>K</given-names></name></person-group><article-title>Post kala-azar dermal leishmaniasis: a neglected aspect of kala-azar control programmes</article-title><source>Ann Trop Med Parasitol</source><year>1992</year><volume>86</volume><fpage>355</fpage><lpage>359</lpage><pub-id pub-id-type="pmid">1463355</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Topuzogullari</surname><given-names>M</given-names></name><name><surname>Koc</surname><given-names>RC</given-names></name><name><surname>Isoglu</surname><given-names>SD</given-names></name><name><surname>Bagirova</surname><given-names>M</given-names></name><name><surname>Akdeste</surname><given-names>Z</given-names></name><name><surname>Elcicek</surname><given-names>S</given-names></name><name><surname>Oztel</surname><given-names>ON</given-names></name><name><surname>Baydar</surname><given-names>SY</given-names></name><name><surname>Ates</surname><given-names>SC</given-names></name><name><surname>Allahverdiyev</surname><given-names>AM</given-names></name></person-group><article-title>Conjugation, characterization and toxicity of lipophosphoglycan-polyacrylic acid conjugate for vaccination against leishmaniasis</article-title><source>J Biomed Sci</source><year>2013</year><volume>20</volume><fpage>35</fpage><pub-id pub-id-type="doi">10.1186/1423-0127-20-35</pub-id><pub-id pub-id-type="pmid">23731716</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaur</surname><given-names>J</given-names></name><name><surname>Kaur</surname><given-names>T</given-names></name><name><surname>Kaur</surname><given-names>S</given-names></name></person-group><article-title>Studies on the protective efficacy and immunogenicity of Hsp70 and Hsp83 based vaccine formulations in Leishmania donovani infected BALB/c mice</article-title><source>Acta Trop</source><year>2011</year><volume>119</volume><fpage>50</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.actatropica.2011.04.007</pub-id><pub-id pub-id-type="pmid">21530477</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdian</surname><given-names>N</given-names></name><name><surname>Gholami</surname><given-names>E</given-names></name><name><surname>Zahedifard</surname><given-names>F</given-names></name><name><surname>Safaee</surname><given-names>N</given-names></name><name><surname>Rafati</surname><given-names>S</given-names></name></person-group><article-title>Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis</article-title><source>Experimental Parasitol</source><year>2011</year><volume>127</volume><fpage>627</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1016/j.exppara.2010.12.007</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salazara</surname><given-names>MBM</given-names></name><name><surname>Dom&#x000ed;ngueza</surname><given-names>JD</given-names></name><name><surname>Estradaa</surname><given-names>JS</given-names></name><name><surname>Bonillab</surname><given-names>CG</given-names></name><name><surname>Becker</surname><given-names>I</given-names></name></person-group><article-title>Vaccination with Leishmania mexicana LPG induces PD-1 in CD8+ and PD-L2 in macrophages thereby suppressing the immune response: a model to assess vaccine efficacy</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><fpage>1259</fpage><lpage>1265</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.01.016</pub-id><pub-id pub-id-type="pmid">24462405</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carri&#x000f3;n</surname><given-names>J</given-names></name><name><surname>Folgueira</surname><given-names>C</given-names></name><name><surname>Soto</surname><given-names>M</given-names></name><name><surname>Fresno</surname><given-names>M</given-names></name><name><surname>Requena</surname><given-names>JM</given-names></name></person-group><article-title>Leishmania infantum HSP70-II null mutant as candidate vaccine against leishmaniasis: a preliminary evaluation</article-title><source>Parasites Vectors</source><year>2011</year><volume>4</volume><fpage>150</fpage><pub-id pub-id-type="doi">10.1186/1756-3305-4-150</pub-id><pub-id pub-id-type="pmid">21794145</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ait-Oudhia</surname><given-names>K</given-names></name><name><surname>Gazanion</surname><given-names>E</given-names></name><name><surname>Oury</surname><given-names>B</given-names></name><name><surname>Vergnes</surname><given-names>B</given-names></name><name><surname>Sereno</surname><given-names>D</given-names></name></person-group><article-title>The fitness of antimony-resistant Leishmania parasites: lessons from the field</article-title><source>Trends Parasitol</source><year>2011</year><volume>27</volume><fpage>141</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1016/j.pt.2010.12.003</pub-id><pub-id pub-id-type="pmid">21216196</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adam</surname><given-names>GK</given-names></name><name><surname>Abdulla</surname><given-names>MA</given-names></name><name><surname>Ahmed</surname><given-names>AA</given-names></name><name><surname>Adam</surname><given-names>I</given-names></name></person-group><article-title>Maternal and perinatal outcomes of visceral leishmaniasis (kala-azar) treated with sodium stibogluconate in eastern Sudan</article-title><source>Int J Gynecol Obstet</source><year>2009</year><volume>107</volume><fpage>208</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1016/j.ijgo.2009.08.002</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dorlo</surname><given-names>TPC</given-names></name><name><surname>Kager</surname><given-names>PA</given-names></name></person-group><article-title>Comment on: cutaneous and mucocutaneous leishmaniasis in Tigray, northern Ethiopia: clinical aspects and therapeutic concerns</article-title><source>Trans R Soc Trop Med Hyg</source><year>2010</year><volume>104</volume><fpage>84</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.trstmh.2009.07.022</pub-id><pub-id pub-id-type="pmid">19836815</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>PG</given-names></name><name><surname>Barrett</surname><given-names>MP</given-names></name><name><surname>Ward</surname><given-names>SA</given-names></name><name><surname>Koning</surname><given-names>HP</given-names></name></person-group><article-title>Pentamidine uptake and resistance in pathogenic protozoa: past, present and future</article-title><source>Trends Parasitol</source><year>2003</year><volume>19</volume><fpage>232</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1016/S1471-4922(03)00069-2</pub-id><pub-id pub-id-type="pmid">12763430</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben Salah</surname><given-names>A</given-names></name><name><surname>Buffet</surname><given-names>PA</given-names></name><name><surname>Morizot</surname><given-names>G</given-names></name><name><surname>Ben Massoud</surname><given-names>N</given-names></name><name><surname>Zaatour</surname><given-names>A</given-names></name><name><surname>Ben Alaya</surname><given-names>N</given-names></name><name><surname>Hamida</surname><given-names>NBH</given-names></name><name><surname>El Ahmadi</surname><given-names>Z</given-names></name><name><surname>Downs</surname><given-names>MT</given-names></name><name><surname>Smith</surname><given-names>PL</given-names></name><name><surname>Dellagi</surname><given-names>K</given-names></name><name><surname>Grogl</surname><given-names>M</given-names></name></person-group><article-title>WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo-controlled study</article-title><source>PLoS Negl Trop Dis</source><year>2009</year><volume>3</volume><fpage>e432</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0000432</pub-id><pub-id pub-id-type="pmid">19415122</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sundar</surname><given-names>S</given-names></name><name><surname>Sinha</surname><given-names>PK</given-names></name><name><surname>Rai</surname><given-names>M</given-names></name><name><surname>Verma</surname><given-names>DK</given-names></name><name><surname>Nawin</surname><given-names>K</given-names></name><name><surname>Alam</surname><given-names>S</given-names></name><name><surname>Chakravarty</surname><given-names>J</given-names></name><name><surname>Vaillant</surname><given-names>M</given-names></name><name><surname>Verma</surname><given-names>N</given-names></name><name><surname>Pandey</surname><given-names>K</given-names></name><name><surname>Kumari</surname><given-names>P</given-names></name><name><surname>Lal</surname><given-names>CS</given-names></name><name><surname>Arora</surname><given-names>R</given-names></name><name><surname>Sharma</surname><given-names>B</given-names></name><name><surname>Ellis</surname><given-names>S</given-names></name><name><surname>Strub-Wourgaft</surname><given-names>N</given-names></name><name><surname>Balasegaram</surname><given-names>M</given-names></name><name><surname>Olliaro</surname><given-names>P</given-names></name><name><surname>Das</surname><given-names>P</given-names></name><name><surname>Modabber</surname><given-names>F</given-names></name></person-group><article-title>Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial</article-title><source>Lancet</source><year>2011</year><volume>377</volume><fpage>477</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(10)62050-8</pub-id><pub-id pub-id-type="pmid">21255828</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melaku</surname><given-names>Y</given-names></name><name><surname>Collin</surname><given-names>SM</given-names></name><name><surname>Keus</surname><given-names>K</given-names></name><name><surname>Gatluak</surname><given-names>F</given-names></name><name><surname>Ritmeijer</surname><given-names>K</given-names></name><name><surname>Davidson</surname><given-names>RN</given-names></name></person-group><article-title>Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy</article-title><source>Am J Trop Med Hyg</source><year>2007</year><volume>77</volume><fpage>89</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">17620635</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adib</surname><given-names>M</given-names></name><name><surname>Ansari</surname><given-names>S</given-names></name><name><surname>Mohammadi</surname><given-names>A</given-names></name><name><surname>Bijanzadeh</surname><given-names>HR</given-names></name></person-group><article-title>A novel, one-pot, solvent and catalyst-free synthesis of 2-aryl/alkyl-4(3H)-quinazolinones</article-title><source>Tetrahedron Lett</source><year>2010</year><volume>51</volume><fpage>30</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.tetlet.2009.06.034</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>M</given-names></name><name><surname>Sharma</surname><given-names>K</given-names></name><name><surname>Sharma</surname><given-names>DK</given-names></name></person-group><article-title>Diversity oriented one-pot three-component sequential synthesis of annulated benzothiazoloquinazolines</article-title><source>Org Med Chem Lett</source><year>2012</year><volume>2</volume><fpage>10</fpage><pub-id pub-id-type="doi">10.1186/2191-2858-2-10</pub-id><pub-id pub-id-type="pmid">22381142</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nouira</surname><given-names>I</given-names></name><name><surname>Kostakis</surname><given-names>IK</given-names></name><name><surname>Dubouilh</surname><given-names>C</given-names></name><name><surname>Chosson</surname><given-names>E</given-names></name><name><surname>Iannelli</surname><given-names>M</given-names></name><name><surname>Besson</surname><given-names>T</given-names></name></person-group><article-title>Decomposition of formamide assisted by microwaves, a tool for synthesis of nitrogen-containing heterocycles</article-title><source>Tetrahedron Lett</source><year>2008</year><volume>49</volume><fpage>7033</fpage><lpage>7036</lpage><pub-id pub-id-type="doi">10.1016/j.tetlet.2008.09.135</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>C</given-names></name><name><surname>You</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>XF</given-names></name><name><surname>You</surname><given-names>R</given-names></name><name><surname>Weng</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Design, synthesis and anticoccidial activity of a series of 3-(2-(2-methoxyphenyl)-2-oxoethyl) quinazolinone derivatives</article-title><source>Pestic Biochem Physiol</source><year>2010</year><volume>97</volume><fpage>194</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1016/j.pestbp.2010.02.001</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Omar</surname><given-names>MA</given-names></name><name><surname>Conrad</surname><given-names>J</given-names></name><name><surname>Beifuss</surname><given-names>U</given-names></name></person-group><article-title>Copper-catalyzed domino reaction between 1-(2-halophenyl)methanamines and amidines or imidates for the synthesis of 2-substituted quinazolinones</article-title><source>Tetrahedron</source><year>2014</year><volume>70</volume><fpage>3061</fpage><lpage>3072</lpage><pub-id pub-id-type="doi">10.1016/j.tet.2014.02.066</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Safaei</surname><given-names>HR</given-names></name><name><surname>Shekouhy</surname><given-names>M</given-names></name><name><surname>Shafiee</surname><given-names>V</given-names></name><name><surname>Davoodi</surname><given-names>M</given-names></name></person-group><article-title>Glycerol based ionic liquid with a borone core: a new highly efficient and reusable promoting medium for the synthesis of quinazolinones</article-title><source>J Mol Liq</source><year>2013</year><volume>180</volume><fpage>139</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1016/j.molliq.2013.01.013</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>C</given-names></name><name><surname>Shah</surname><given-names>S</given-names></name><name><surname>Hughes</surname><given-names>BL</given-names></name><name><surname>Nikov</surname><given-names>GN</given-names></name><name><surname>Crispino</surname><given-names>JL</given-names></name><name><surname>Middleton</surname><given-names>RE</given-names></name><name><surname>Szewczak</surname><given-names>AA</given-names></name><name><surname>Munoz</surname><given-names>B</given-names></name><name><surname>Shearman</surname><given-names>MS</given-names></name></person-group><article-title>Quinazolinones as &#x003b3;-secretase modulators</article-title><source>Bioorg Med Chem Lett</source><year>2011</year><volume>21</volume><fpage>773</fpage><lpage>776</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2010.11.111</pub-id><pub-id pub-id-type="pmid">21190851</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manivannan</surname><given-names>E</given-names></name><name><surname>Chaturvedi</surname><given-names>SC</given-names></name></person-group><article-title>Analogue-based design, synthesis and molecular docking analysis of 2,3-diarylquinazolinones as non-ulcerogenic anti-inflammatory agents</article-title><source>Bioorg Med Chem</source><year>2011</year><volume>19</volume><fpage>4520</fpage><lpage>4528</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2011.06.019</pub-id><pub-id pub-id-type="pmid">21724403</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhee</surname><given-names>H-K</given-names></name><name><surname>Yoo</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>E</given-names></name><name><surname>Kwon</surname><given-names>YJ</given-names></name><name><surname>Seo</surname><given-names>H-R</given-names></name><name><surname>Lee</surname><given-names>Y-S</given-names></name><name><surname>Choo</surname><given-names>H-YP</given-names></name></person-group><article-title>Synthesis and cytotoxicity of 2-phenylquinazolin-4(3H)-one derivatives</article-title><source>Eur J Med Chem</source><year>2011</year><volume>46</volume><fpage>3900</fpage><lpage>3909</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2011.05.061</pub-id><pub-id pub-id-type="pmid">21704436</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Jagani CL, Sojitra NA, Vanparia SF, Patel TS, Dixit RB, Dixit BC: <bold>Microwave promoted synthesis and antimicrobial activity of 3-thiazole substituted 2-styryl-4(3H)-quinazolinone derivatives.</bold><italic>J Saudi Chem Soc</italic>. doi:10.1016/j.jscs.2011.02.001</mixed-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shivananda</surname><given-names>MK</given-names></name><name><surname>Holla</surname><given-names>BS</given-names></name></person-group><article-title>Antifungal activity studies of some quinazolinone derivatives</article-title><source>J Chem Pharm Res</source><year>2011</year><volume>3</volume><fpage>83</fpage><lpage>86</lpage></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x00160;pul&#x000e1;k</surname><given-names>M</given-names></name><name><surname>Pourov&#x000e1;</surname><given-names>J</given-names></name><name><surname>Vopr&#x00161;&#x000e1;lov&#x000e1;</surname><given-names>M</given-names></name><name><surname>Miku&#x00161;ek</surname><given-names>J</given-names></name><name><surname>Kune&#x00161;</surname><given-names>J</given-names></name><name><surname>Vacek</surname><given-names>J</given-names></name><name><surname>Ghavre</surname><given-names>M</given-names></name><name><surname>Gathergood</surname><given-names>N</given-names></name><name><surname>Pour</surname><given-names>M</given-names></name></person-group><article-title>Novel bronchodilatory quinazolines and quinoxalines: synthesis and biological evaluation</article-title><source>Eur J Med Chem</source><year>2014</year><volume>74</volume><fpage>65</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2013.12.024</pub-id><pub-id pub-id-type="pmid">24445313</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berman</surname><given-names>JD</given-names></name><name><surname>King</surname><given-names>M</given-names></name><name><surname>Edwards</surname><given-names>N</given-names></name></person-group><article-title>Antileishmanial activities of 2,4-diaminoquinazoline putative dihydrofolate reductase inhibitors</article-title><source>Antimicrobial Agents Chemother</source><year>1989</year><volume>33</volume><fpage>1860</fpage><lpage>1863</lpage><pub-id pub-id-type="doi">10.1128/AAC.33.11.1860</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharjee</surname><given-names>AK</given-names></name><name><surname>Skanchy</surname><given-names>DJ</given-names></name><name><surname>Jennings</surname><given-names>B</given-names></name><name><surname>Hudson</surname><given-names>TH</given-names></name><name><surname>Brendle</surname><given-names>JJ</given-names></name><name><surname>Werbovetz</surname><given-names>KA</given-names></name></person-group><article-title>Analysis of stereoelectronic properties, mechanism of action and pharmacophore of synthetic indolo [2,1-b]quinazoline-6,12-dione derivatives in relation to antileishmanial activity using quantum chemical, cyclic voltammetry and 3-D-QSAR catalyst procedures</article-title><source>Bioorg Med Chem</source><year>2002</year><volume>10</volume><fpage>1979</fpage><lpage>1989</lpage><pub-id pub-id-type="doi">10.1016/S0968-0896(02)00013-5</pub-id><pub-id pub-id-type="pmid">11937358</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arfan</surname><given-names>M</given-names></name><name><surname>Khan</surname><given-names>R</given-names></name><name><surname>Khan</surname><given-names>MA</given-names></name><name><surname>Anjum</surname><given-names>S</given-names></name><name><surname>Choudhary</surname><given-names>MI</given-names></name><name><surname>Ahmad</surname><given-names>M</given-names></name></person-group><article-title>Synthesis and antileishmanial and antimicrobial activities of some 2,3-disubstituted 3H-quinazolin-4-ones</article-title><source>J Enzyme Inhib Med Chem</source><year>2010</year><volume>25</volume><fpage>451</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.3109/14756360903309412</pub-id><pub-id pub-id-type="pmid">20235747</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleita</surname><given-names>DH</given-names></name><name><surname>Mohareb</surname><given-names>RM</given-names></name><name><surname>Sakka</surname><given-names>OK</given-names></name></person-group><article-title>Antitumor and antileishmanial evaluation of novel heterocycles derived from quinazoline scaffold: a molecular modeling approach</article-title><source>Med Chem Res</source><year>2013</year><volume>22</volume><fpage>2207</fpage><lpage>2221</lpage><pub-id pub-id-type="doi">10.1007/s00044-012-0213-9</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lara</surname><given-names>O</given-names></name><name><surname>Raquel</surname><given-names>E</given-names></name><name><surname>Mar&#x000ed;a</surname><given-names>A</given-names></name><name><surname>Juan</surname><given-names>J</given-names></name><name><surname>Francisco</surname><given-names>B</given-names></name><name><surname>Jos&#x000e9;</surname><given-names>M</given-names></name></person-group><article-title>In vitro effect of new formulations of amphotericin B on amastigote and promastigote forms of Leishmania infantum</article-title><source>Int J Antimicrob Agents</source><year>2007</year><volume>30</volume><fpage>325</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2007.05.013</pub-id><pub-id pub-id-type="pmid">17631982</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tariku</surname><given-names>Y</given-names></name><name><surname>Hymete</surname><given-names>A</given-names></name><name><surname>Hailu</surname><given-names>A</given-names></name><name><surname>Rohloff</surname><given-names>J</given-names></name></person-group><article-title>Essential-oil composition, antileishmanial and toxicity study of Artemisia abyssinica and Satureja punctata ssp. punctata from Ethiopia</article-title><source>Chem Biodivers</source><year>2010</year><volume>7</volume><fpage>1013</fpage><lpage>1016</lpage><pub-id pub-id-type="doi">10.1002/cbdv.200900375</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorke</surname><given-names>D</given-names></name></person-group><article-title>A new approach to practical acute toxicity test</article-title><source>Arch Toxicol</source><year>1983</year><volume>54</volume><fpage>275</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1007/BF01234480</pub-id><pub-id pub-id-type="pmid">6667118</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakayama</surname><given-names>GR</given-names></name><name><surname>Caton</surname><given-names>MC</given-names></name><name><surname>Nova</surname><given-names>MP</given-names></name><name><surname>Parandoosh</surname><given-names>Z</given-names></name></person-group><article-title>Assessment of the Alamar Blue assay for cellular growth and viability in vitro</article-title><source>J Immunol Methods</source><year>1997</year><volume>204</volume><fpage>205</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1016/S0022-1759(97)00043-4</pub-id><pub-id pub-id-type="pmid">9212838</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Nasiry</surname><given-names>S</given-names></name><name><surname>Geusens</surname><given-names>N</given-names></name><name><surname>Hanssens</surname><given-names>M</given-names></name><name><surname>Luyten</surname><given-names>C</given-names></name><name><surname>Pijnenborg</surname><given-names>R</given-names></name></person-group><article-title>The use of Alamar Blue assay for quantitative analysis of viability, migration and invasion of choriocarcinoma cells</article-title><source>Hum Reprod</source><year>2007</year><volume>25</volume><fpage>1</fpage><lpage>6</lpage></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimony</surname><given-names>O</given-names></name><name><surname>Jaffe</surname><given-names>CL</given-names></name></person-group><article-title>Rapid fluorescent assay for screening drugs on Leishmania amastigotes</article-title><source>J Microbiol Methods</source><year>2006</year><volume>75</volume><fpage>196</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1016/j.mimet.2008.05.026</pub-id><pub-id pub-id-type="pmid">18573286</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Bajaj</surname><given-names>K</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Panwar</surname><given-names>H</given-names></name><name><surname>Singh</surname><given-names>T</given-names></name><name><surname>Srivastava</surname><given-names>VK</given-names></name></person-group><article-title>Some new 2,3,6-trisubstituted quinazolinones as potent anti-inflammatory, analgesic and COX-II inhibitors</article-title><source>Bioorg Med Chem</source><year>2003</year><volume>11</volume><fpage>5293</fpage><lpage>5299</lpage><pub-id pub-id-type="doi">10.1016/S0968-0896(03)00501-7</pub-id><pub-id pub-id-type="pmid">14604693</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Errede</surname><given-names>LA</given-names></name></person-group><article-title>Acylanthranils 1. The pathway of quinazolone formation in the reaction of acylanthranils with anilines</article-title><source>J Org Chem</source><year>1976</year><volume>41</volume><fpage>1763</fpage><lpage>1765</lpage><pub-id pub-id-type="doi">10.1021/jo00872a021</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raffa</surname><given-names>D</given-names></name><name><surname>Edler</surname><given-names>MC</given-names></name><name><surname>Daidone</surname><given-names>G</given-names></name><name><surname>Maggio</surname><given-names>B</given-names></name><name><surname>Merickech</surname><given-names>M</given-names></name><name><surname>Plescia</surname><given-names>S</given-names></name><name><surname>Schillaci</surname><given-names>D</given-names></name><name><surname>Bai</surname><given-names>R</given-names></name><name><surname>Hamel</surname><given-names>E</given-names></name></person-group><article-title>Synthesis, cytotoxicity, and inhibitory effects on tubulin polymerization of a new 3-heterocyclo substituted 2-styrylquinazolinones</article-title><source>Eur J Med Chem</source><year>2004</year><volume>39</volume><fpage>299</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2003.12.009</pub-id><pub-id pub-id-type="pmid">15072839</pub-id></element-citation></ref></ref-list></back></article>